BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 17991895)

  • 1. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
    Palii SS; Van Emburgh BO; Sankpal UT; Brown KD; Robertson KD
    Mol Cell Biol; 2008 Jan; 28(2):752-71. PubMed ID: 17991895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells.
    Vispé S; Deroide A; Davoine E; Desjobert C; Lestienne F; Fournier L; Novosad N; Bréand S; Besse J; Busato F; Tost J; De Vries L; Cussac D; Riond J; Arimondo PB
    Oncotarget; 2015 Jun; 6(17):15265-82. PubMed ID: 25948775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors.
    Beyrouthy MJ; Garner KM; Hever MP; Freemantle SJ; Eastman A; Dmitrovsky E; Spinella MJ
    Cancer Res; 2009 Dec; 69(24):9360-6. PubMed ID: 19951990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity of 5-Aza-2'-deoxycytidine against gastric cancer involves DNA damage in an ATM-P53 dependent signaling pathway and demethylation of P16(INK4A).
    Liu J; Xie YS; Wang FL; Zhang LJ; Zhang Y; Luo HS
    Biomed Pharmacother; 2013 Feb; 67(1):78-87. PubMed ID: 23201008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-aza-2'-deoxycytidine-induced genome rearrangements are mediated by DNMT1.
    Maslov AY; Lee M; Gundry M; Gravina S; Strogonova N; Tazearslan C; Bendebury A; Suh Y; Vijg J
    Oncogene; 2012 Dec; 31(50):5172-9. PubMed ID: 22349820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methyltransferase 1 knockdown activates a replication stress checkpoint.
    Unterberger A; Andrews SD; Weaver IC; Szyf M
    Mol Cell Biol; 2006 Oct; 26(20):7575-86. PubMed ID: 17015478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
    McNeely S; Conti C; Sheikh T; Patel H; Zabludoff S; Pommier Y; Schwartz G; Tse A
    Cell Cycle; 2010 Mar; 9(5):995-1004. PubMed ID: 20160494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
    Valdez BC; Nieto Y; Murray D; Li Y; Wang G; Champlin RE; Andersson BS
    Exp Hematol; 2012 Oct; 40(10):800-10. PubMed ID: 22687754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirement of MTA1 in ATR-mediated DNA damage checkpoint function.
    Li DQ; Ohshiro K; Khan MN; Kumar R
    J Biol Chem; 2010 Jun; 285(26):19802-12. PubMed ID: 20427275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional interaction of H2AX, NBS1, and p53 in ATM-dependent DNA damage responses and tumor suppression.
    Kang J; Ferguson D; Song H; Bassing C; Eckersdorff M; Alt FW; Xu Y
    Mol Cell Biol; 2005 Jan; 25(2):661-70. PubMed ID: 15632067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions.
    Orta ML; Höglund A; Calderón-Montaño JM; Domínguez I; Burgos-Morón E; Visnes T; Pastor N; Ström C; López-lázaro M; Helleday T
    Nucleic Acids Res; 2014 Aug; 42(14):9108-20. PubMed ID: 25074383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal.
    Ghoshal K; Datta J; Majumder S; Bai S; Kutay H; Motiwala T; Jacob ST
    Mol Cell Biol; 2005 Jun; 25(11):4727-41. PubMed ID: 15899874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma.
    Geiger K; Hagenbuchner J; Rupp M; Fiegl H; Sergi C; Meister B; Kiechl-Kohlendorfer U; Müller T; Ausserlechner MJ; Obexer P
    Mol Biol Cell; 2012 Jun; 23(11):2226-34. PubMed ID: 22493319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
    Pabla N; Huang S; Mi QS; Daniel R; Dong Z
    J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The radiomimetic enediyne C-1027 induces unusual DNA damage responses to double-strand breaks.
    Kennedy DR; Beerman TA
    Biochemistry; 2006 Mar; 45(11):3747-54. PubMed ID: 16533058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage.
    Helt CE; Cliby WA; Keng PC; Bambara RA; O'Reilly MA
    J Biol Chem; 2005 Jan; 280(2):1186-92. PubMed ID: 15533933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase.
    Stojic L; Mojas N; Cejka P; Di Pietro M; Ferrari S; Marra G; Jiricny J
    Genes Dev; 2004 Jun; 18(11):1331-44. PubMed ID: 15175264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response.
    Maude SL; Enders GH
    Cancer Res; 2005 Feb; 65(3):780-6. PubMed ID: 15705874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataxia telangiectasia-mutated-Rad3-related DNA damage checkpoint signaling pathway triggered by hepatitis B virus infection.
    Zhao F; Hou NB; Yang XL; He X; Liu Y; Zhang YH; Wei CW; Song T; Li L; Ma QJ; Zhong H
    World J Gastroenterol; 2008 Oct; 14(40):6163-70. PubMed ID: 18985806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine.
    Thottassery JV; Sambandam V; Allan PW; Maddry JA; Maxuitenko YY; Tiwari K; Hollingshead M; Parker WB
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):291-302. PubMed ID: 24908436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.